ELISA News and Research

RSS

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

In the current study, the authors evaluate several different competitive ELISAs that could be used to measure serum antibodies.

11 Aug 2021

Activation of NLRP3 inflammasome by the N protein of SARS-CoV-2 to induce hyperinflammation

A new study has revealed the mechanism by which the SARS-CoV-2 N protein activates NLRP3 inflammasomes to induce hyperinflammation.

5 Aug 2021

COVID vaccines generate antibodies in saliva

Researchers in the United States and Canada have conducted a study showing that the vaccines developed by Pfizer-BioNTech and Moderna to protect against coronavirus disease 2019 (COVID-19) generate local antibody responses in the salivary gland that are independent of the systemic immune response.

5 Aug 2021

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Researchers remain perplexed as to why some patients infected with SARS-CoV-2, the virus responsible for COVID-19, remain asymptomatic while other patients develop severe disease symptoms.

5 Aug 2021

Monoclonal antibody could inform development of pan-coronavirus vaccines

Researchers in the United States have demonstrated the potential of a monoclonal antibody to inform the design of pan-coronavirus vaccines that could prevent the outbreak of future pandemics such as coronavirus disease 2019 (COVID-19).

4 Aug 2021

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.

3 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

A team of international scientists has recently developed virus-like particles (VLPs) by coating liposomes with the synthetic spike glycoprotein of SARS-CoV-2.

28 Jul 2021

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

A new study describes how immunocompromised vaccine recipients may not always respond as expected to the COVID-19 vaccine.

27 Jul 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

A new study published in the journal Biotechnology and Applied Biochemistry deals with the development of a time-resolved fluorescence immunoassay (TRFIA) for the detection of total COVID-19 antibodies in humans.

15 Jul 2021

Neutralizing aptamers block SARS-CoV-2 infection in vitro

A new study describes the clinical utility of aptamers against SARS-CoV-2.

13 Jul 2021

Blood test could be a simple and effective method for monitoring SARS-CoV-2 infection

A blood test that quantifies the protein ACE2, the cellular protein which allows entry of the coronavirus into cells, as well as ACE2 fragments, produced as a result of interaction with the virus, could be a simple and effective method for monitoring SARS-CoV-2 infection, according to a study led by Javier Sáez-Valero, from the UMH-CSIC Neurosciences Institute in Alicante, published in FASEB Journal.

13 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Researchers in the United States have conducted a study suggesting that individuals fully vaccinated against coronavirus disease 2019 (COVID-19) who develop breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are less likely to transmit the virus to others than unvaccinated infected individuals.

8 Jul 2021

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.

7 Jul 2021

ELISA News and Research

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

Evaluation of mRNA vaccine responses with a surrogate SARS-CoV-2 viral neutralization assay

Activation of NLRP3 inflammasome by the N protein of SARS-CoV-2 to induce hyperinflammation

COVID vaccines generate antibodies in saliva

Specific and sensitive biomarker in the blood predicts symptomatic COVID-19 infection

Monoclonal antibody could inform development of pan-coronavirus vaccines

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

Spike-containing virus-like particles induce robust sterilizing immunity against SARS-CoV-2 in macaques

Impaired immune response to SARS-CoV-2 mRNA vaccination in immunocompromised patients

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

How do immunocompromised patients respond to COVID-19 vaccines?

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

Neutralizing aptamers block SARS-CoV-2 infection in vitro

Blood test could be a simple and effective method for monitoring SARS-CoV-2 infection

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Study shows antibody titers after natural SARS-CoV-2 infection last longer than previously thought

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News